| Display title | Chemistry:Bunazosin |
| Default sort key | Bunazosin |
| Page length (in bytes) | 2,901 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 544307 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Ohm |
| Date of page creation | 13:06, 19 November 2022 |
| Latest editor | imported>Ohm |
| Date of latest edit | 13:06, 19 November 2022 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Bunazosin (INN) is an α1-adrenergic receptor antagonist. Bunazosin was initially developed to treat benign prostatic hyperplasia (BPH). It has been approved in Japan in a topical form to treat glaucoma. The mechanism of action is a reduction of aqueous outflow through the uveoscleral pathway resulting... |
